Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

My first 24 hours with Siri AI on the Mac

June 13, 2026

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zscaler

June 13, 2026

Never Post’s Mike Rugnetta on the creative process and the value of reliable power

June 13, 2026

BTGO EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds BitGo Holdings (BTGO) Investors of Securities Class Action Lawsuit Deadline on August 7, 2026

June 13, 2026

FemiCore (Official Website & Authenticity Notice 2026) – Counterfeit Risks and What Consumers Should Know

June 13, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » Alembic Therapeutics, LLC Announces Acquisition of NUVESSA® (metronidazole vaginal gel 1.3%) from Exeltis USA, Inc.
Press Release

Alembic Therapeutics, LLC Announces Acquisition of NUVESSA® (metronidazole vaginal gel 1.3%) from Exeltis USA, Inc.

By News RoomJune 9, 20262 Mins Read
Alembic Therapeutics, LLC Announces Acquisition of NUVESSA® (metronidazole vaginal gel 1.3%) from Exeltis USA, Inc.
Share
Facebook Twitter LinkedIn Pinterest Email

BEDMINSTER, N.J., June 09, 2026 (GLOBE NEWSWIRE) — Alembic Therapeutics, LLC announces the acquisition of NUVESSA® (metronidazole vaginal gel 1.3%), an FDA-approved prescription medication indicated for the treatment of bacterial vaginal infections in females 12 years of age and older, from Exeltis USA, Inc. This acquisition represents an important milestone in Alembic Therapeutics’ ongoing commitment to expanding its women’s health portfolio and increasing patient access to proven treatment options. Through this transaction, Alembic Therapeutics assumes responsibility for the commercialization and distribution of NUVESSA in the United States.

NUVESSA is indicated for the treatment of bacterial vaginosis in females 12 years of age and older. NUVESSA is designed as a convenient single-dose, pre-filled disposable applicator, which delivers approximately 5g of gel containing 65mg of metronidazole, administered once a day at bedtime intravaginally. NUVESSA is contraindicated in persons who have shown hypersensitivity to metronidazole, parabens, any component of the formulation, or other nitroimidazole derivatives.

NUVESSA will continue to be available nationwide through retail and specialty pharmacy distribution channels. Healthcare providers can continue prescribing NUVESSA in accordance with the approved prescribing information for appropriate patients. The full prescribing information should be consulted for complete details regarding approved indications, dosing, administration, contraindications, warnings, and safety information.

Alembic Therapeutics is dedicated to delivering high-quality pharmaceutical products and innovative healthcare solutions that improve patient outcomes and expand access to care across multiple therapeutic categories.

Alembic Therapeutics, LLC
550 Hills Drive, Suite 110
Bedminster NJ 07921
908-569-7456 • [email protected]
www.alembictherapeutics.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7c2b9304-e79b-43e8-8e2c-9cb1ad8774ae

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zscaler

BTGO EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds BitGo Holdings (BTGO) Investors of Securities Class Action Lawsuit Deadline on August 7, 2026

FemiCore (Official Website & Authenticity Notice 2026) – Counterfeit Risks and What Consumers Should Know

BMI EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Badger Meter (BMI) Investors of Securities Class Action Lawsuit Deadline on August 3, 2026

Hyderabad Sees Surge in Dining Table Rentals in 2026 as Salaried IT Professionals Reject ₹45,000 EMI Lock-Ins for ₹1,400/Month Plans From Rentomojo

PHR EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Phreesia (PHR) Investors of Securities Class Action Lawsuit Deadline on July 13, 2026

RBLX EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Notifies Roblox (RBLX) Investors of Securities Class Action Lawsuit Deadline on August 7, 2026

Don’t Pay Full Price for Power: WattCycle’s Prime Day Event Drops Up to 70% Off LiFePO4 Batteries Starting June 15

AVAV EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds AeroVironment (AVAV) Investors of Securities Class Action Lawsuit Deadline on July 27, 2026

Editors Picks

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zscaler

June 13, 2026

Never Post’s Mike Rugnetta on the creative process and the value of reliable power

June 13, 2026

BTGO EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds BitGo Holdings (BTGO) Investors of Securities Class Action Lawsuit Deadline on August 7, 2026

June 13, 2026

FemiCore (Official Website & Authenticity Notice 2026) – Counterfeit Risks and What Consumers Should Know

June 13, 2026

Latest News

BMI EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Badger Meter (BMI) Investors of Securities Class Action Lawsuit Deadline on August 3, 2026

June 13, 2026

Hyderabad Sees Surge in Dining Table Rentals in 2026 as Salaried IT Professionals Reject ₹45,000 EMI Lock-Ins for ₹1,400/Month Plans From Rentomojo

June 13, 2026

Pool is a better app for managing all your screenshots

June 13, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version